decorational arrow GLP-1 | 2 min. read

Life's a balancing act – life, work, and type 2 diabetes

The continued search for balance

Health doesn't exist in a vacuum. This might sound obvious, but it's worth reflecting that health comes alongside everything else in your life. You’re constantly juggling many responsibilities from one moment to the next, striving to find the right balance between work, family, social commitments and everyday routines. Living with type 2 diabetes is another thing to juggle, but it shouldn’t get in the way of living your life.

With type 2 diabetes, your body may not respond effectively to a naturally occurring hormone called Glucagon-like peptide 1 (GLP-1). GLP-1 increases insulin levels when it's needed, thereby lowering blood sugar levels. GLP-1 can also reduce food consumption, body weight and increase satiety. Researchers are also looking into the role of GLP-1 in the risk of cardiovascular events, such as heart disease and stroke.

It can be hard for someone with type 2 diabetes to be in tune with their body when it doesn’t respond as well as it should to GLP-1. But, what if your body worked in partnership with you, leaving you more free to focus on other things in life rather than type 2 diabetes?

The Perfect Partner

When your body works in partnership, managing type 2 diabetes can become one less thing to juggle. Whether you are living with type 2 diabetes or care for someone who is – speak to your doctor about treatment options.

References
  1. Salehi M, Aulinger B, Prigeon RL, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010; 59:1330-1337.
  2. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43:1664-1669.
  3. Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30:72-130.
  4. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101:515-520.
  5. Shah M and Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014; 15:181-187.
  6. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:311-322.
  7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375:1834-1844.
  8. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394:121-130.
  9. Bellastella G, Maiorino MI, Longo M, et al. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta- Analysis. Stroke. 2020; 51:666-669.
  10. Barkas F, Elisaf M and Milionis H. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. Eur J Neurol. 2019; 26:559-565.
  11. Clinicaltrials.gov. A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL). Available at: https://clinicaltrials.gov/ct2/show/NCT03914326. Last accessed: December 2020.
  12. ClinicalTrials.gov. A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE). Available at: https://clinicaltrials.gov/ct2/show/NCT04560998. Last accessed: December 2020.
  13. ClinicalTrials.gov. Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT). Available at: https://clinicaltrials.gov/ct2/show/NCT03574597. Last accessed: December2020.
  14. ClinicalTrials.gov. A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). Available at: https://clinicaltrials.gov/ct2/show/NCT03819153. Last accessed: December 2020. 

Related articles